Editas Medicine (EDIT) Restructuring Costs (2024 - 2025)

Editas Medicine (EDIT) reported Restructuring Costs of $26.1 million for Q2 2025, down 36.16% quarter-over-quarter from $40.9 million in Q1 2025.

Editas Medicine (EDIT) Restructuring Costs (2024 - 2025) Analysis & Trends

Editas Medicine (EDIT) has 2 years of Restructuring Costs data on file, last reported at $26.1 million in Q2 2025.

Restructuring Costs for Q2 2025 came in at $26.1 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $79.2 million (changed N/A YoY), and the FY2024 annual result was $12.2 million, changed N/A from the prior year.
Restructuring Costs retreated to $26.1 million in Q2 2025 per EDIT's latest filing, from $40.9 million in the prior quarter.
Over five years, Restructuring Costs peaked at $40.9 million in Q1 2025 and troughed at $12.2 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Editas Medicine	262.77 Mn	262.77 Mn	-

Download Data